Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 154, Issue 6, 2006, Pages 883-890

  Dagre, Anna ^a,b   Lekakis, J ^a   Mihas, C ^a   Protogerou, A ^a   Thalassinou, L ^a   Tryfonopoulos, D ^a   Douridas, G ^a   Papamichael, C ^a   Alevizaki, M ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ARTERY RESISTANCE; ARTICLE; ATTENUATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DESCRIPTIVE RESEARCH; ENDOTHELIAL DYSFUNCTION; FEMALE; FUNCTIONAL ASSESSMENT; HEART PROTECTION; HIRSUTISM; HOMEOSTASIS; HUMAN; HYPEREMIA; INSULIN RESISTANCE; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; DEHYDROEPIANDROSTERONE SULFATE; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HIRSUTISM; HUMANS; HYPEREMIA; PLETHYSMOGRAPHY; POLYCYSTIC OVARY SYNDROME; REGIONAL BLOOD FLOW;

EID: 33745726758     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02153     Document Type: Article

References (56)

1. Ovalle F & Azziz R. Insulin resistance, polycystic ovary syndrome and type 2 diabetes mellitus. Fertility Sterility 2002 77 1095-1105.
2. Wild R, Painter P, Coulson P, Carruth K & Ranney G. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1985 61 946-951.
3. Holte J, Gennarelli G, Berne C, Bergh T & Lithell H. Elevated ambulatory day time blood pressure in women with polycystic ovary syndrome: a sign of pre-hypertensive state? Human Reproduction 1996 11 23-28.
4. Orio F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G & Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational analytical, prospective case-control study. Journal of Clinical Endocrinology and Metabolism 2004 89 3696-3701.
5. Wu FC & von Eckardstein A. Androgens and coronary artery disease. Endocrine Reviews 2003 24 183-217.
6. Erdem NT, Ercan M, Akyolcu MC & Gundogdu S. Plasma viscosity is an early cardiovascular risk factor in hirsute women with eumenorrhea or oligomenorrhea. Fertility Sterility 2003 80(5) 1195-1198.
7. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertility Sterility 2004 81(1) 19-25.
8. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19(1) 41-47.
9. Cannon RO, III. Role of nitric oxide in cardiovascular disease: Focus on the endothelium, Clinical Chemistry 1998 44 1809-1819.
10. Dakak N, Husain S, Mulcahy D, Andrews NP, Panza JA, Waclawiw M, Schenke W & Quyyumi AA. Contribution of nitric oxide on reactive hyperaemia. Impact on endothelial dysfunction. Hypertension 1998 32 9-15.
11. Creager MA, Cooke JP, Mendelson ME, Gallagher SJ, Coleman SM, Loscazlo J & Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemic humans. Journal of Clinical Investigation 1990 86 228-234.
12. Chowienczyk PJ, Watts GF, Cockcroft JR & Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992 340 1430-1432.
13. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M, Mantysaari M, Summanen P, Bergholm R, Taskinen M & Yki-Jarvinen H. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999 22 973-981.
14. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, Olschewski M & Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996 93 1346-1353.
15. Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E & Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995 91 1981-1987.
16. Perticone F, Ferraro A, Chello M, Mastroroberto P, Verdecchia P & Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001 104(2) 191-196.
17. London G, Pannier B, Agharazii M, Guerin A, Verbeke F & Marchais S. Forearm reactive hyperemia and mortality in end stage renal disease. Kidney International 2004 65(2) 700-704.
18. Zawadzki SK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In Polycystic Ovary Syndrome, Current Issues in Endocrinology and Metabolism, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam. vol. 4, ch.32, Boston: Blackwell, 1992
19. Ferriman D & Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism 1961 21 1440-1447.
20. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis Model Assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
21. Protogerou A, Lekakis J, Kontoyanni D, Stamatelopoulos K, Tsotsoros N, Papaioannou T, Tryfonopoulos D, Papamichael C & Stamatelopoulos S. Effect of ascorbic acid on forearm reactive hyperemia in patients with hypercholesterolemia. European Journal of Cardiovascular Prevention and Rehabilitation 2004 11(2) 149-154.
22. Lamberts S, van den Beld A & van der Lely A. The endocrinology of age. Science 1997 278 419-424.
23. Kravariti M, Naka K, Kalantaridou S, Kazakos N, Katsouras C, Makrigiannakis A, Paraskevaidis E, Chrousos G, Tsatsoulis A & Michalis L. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 5088-5095.
24. Orio F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G & Colao A. Early impairment of endothelial structure and function in young normal weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 4588-4593.
25. Paradisi G, Steinberg H, Hempfling A, Cronin J, Hook G, Shepard M & Baron A, Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415.
26. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Harasawa Y & Takeshira A. Role of nitric oxide in reactive hyperaemia in human forearm vessels. Circulation 1994 90 2285-2290.
27. Engelke KA, Halliwill DN, Proctor NM, Dietz NM & Joyner MJ. Contribution of nitric oxide and prostaglandins to reactive hyperaemia in the human forearm. Journal of Applied Physiology 1996 81 1807-1814.
28. Cortella A, Zambon S, Sartore S, Piarulli F, Calabro A, Manzato E & Crepaldi G. Calf and forearm blood flow in hypercholesterolemic patients. Angiology 2000 51 309-318.
29. Sabunku T, Vural H, Harma M & Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clinical Biochemistry 2001 34 407-413.
30. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A & Genazzani A. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003 144 3449-3455.
31. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Masahiro N & Ogawa H. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. Journal of Clinical Endocrinology and Metabolism 2003 88 3190-3195.
32. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas I-A, Batakis N, Phenekos C & Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 2740-2746.
33. Meyer C, McGrath B, Cameron J, Kotsopoulos D & Teede H. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90(8) 4630-4635.
34. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML & Nestler JE. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Annals of the New York Academy of Sciences 1995 774 271-280.
35. Arad Y, Badimon JJ, Badimon L, Hembree WC & Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 1989 9 159-166.
36. Gordon GB, Bush DE & Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. Journal of Clinical Investigation 1988 82 712-720.
37. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder W, Sudhir K & Komesaroff PA. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. Journal of Clinical Endocrinology and Metabolism 2002 87 176-181.
38. Labrie F, Belanger A, Simard J, Luu-The V & Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Annals of the New York Academy of Sciences 1995 774 16-28.
39. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO, Jr & Pearson TA. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. Journal of American College of Cardiology 1990 16 862-870.
40. Slowinska-Srzednicka J, Malczewska B, Srzednicki M, Chotkowska E, Brzezinska A, Zgliczynski W, Ossowski M, Jeske W, Zgliczynski S & Sadowski Z. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. Journal of Internal Medicine 1995 237 465-472.
41. Bernini GP, Sagro M, Moretti A, Argenio GF, Barlascini CO, Cristofani R & Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. Journal of Clinical Endocrinology and Metabolism 1999 84 2008-2012.
42. Barrett-Connor E & Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Annals of the New York Academy of Sciences 1995 774 259-270.
43. Berr C, Lafon S, Debuire B, Dartigues JF & Baulieu E-E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological and mental status and short-term mortality: a French community-based study. Proceedings of the National Academy of Sciences of the United States of America 1996 93 13410-13415.
44. Kiechl S, Willeit J, Bonora E, Schwarz S & Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arteriosclerosis Thrombosis and Vascular Biology 2000 20 1094-1100.
45. Meyer C, McGrath BP & Teede H. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2005 90 5711-5716.
46. Worboys S, Kotsopoulos D, Teede H, McGrath B & David SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and independent vasodilatation in post-menopausal women already receiving estrogen. Journal of Clinical Endocrinology and Metabolism 2001 88 158-161.
47. Barrett-Connor EL & Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. British Medical Journal 1995 311 1193-1196.
48. Kelly C, Speirs A, Gould G, Petrie J, Lyall H & Connel J. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 742-746.
49. Mather K, Verma S, Corenblum B & Anderson T. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 1851-1856.
50. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 1997 18 774-800.
51. Steinberg H, Chaker H, Learning R, Johnson A, Brechtel G & Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. Journal of Clinical Investigation 1996 97 2601-2610.
52. Cleland S, Petrie J, Ueda S, Elliott H & Connell J. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clinical and Experimental Pharmacology & Physiology 1998 25 175-184.
53. Paradisi G, Steinberg H, Marguette K, Hook G & Baron A. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 576-580.
54. Vincent D, Ilany J, Kondo T, Naruse K, Fisher S, Kisanuki Y, Bursell S, Yanagisawa M & King G. The role of endothelial insulin signalling in the regulation of vascular tone and insulin resistance. Journal of Clinical Investigation 2003 111 1372-1380.
55. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS. Mortality of woman with polycystic ovary syndrome at long term follow up. Journal of Clinical Epidemiology 1998 51 581-586.
56. Wild SH, Pierpoint T, McKeigue PM & Jacobs HS. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study Clinical Endocrinology 2000 52 595-600.